These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 385880)

  • 61. Development of inhalable hyaluronan/mannitol composite dry powders for flucytosine repositioning in local therapy of lung infections.
    Costabile G; d'Angelo I; d'Emmanuele di Villa Bianca R; Mitidieri E; Pompili B; Del Porto P; Leoni L; Visca P; Miro A; Quaglia F; Imperi F; Sorrentino R; Ungaro F
    J Control Release; 2016 Sep; 238():80-91. PubMed ID: 27449745
    [TBL] [Abstract][Full Text] [Related]  

  • 62. [Sensitivity and resistance of pathogenic yeasts to 5-fluoropyrimidines. I.--Relation between the phenotypes of resistance to 5-fluorocytosine, the serotype of Candida albicans and the ecology of various species of Candida of human origin (author's transl)].
    Drouhet E; Mercier-Soucy L; Montplaisir S
    Ann Microbiol (Paris); 1975; 126B(1):25-39. PubMed ID: 1108732
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Effects of antifungal pretreatment on the susceptibility of Candida albicans to human leukocytes.
    Mínguez Mínguez F; Lima JE; García MT; Prieto J
    Chemotherapy; 1997; 43(5):346-51. PubMed ID: 9309368
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Antifungal Efficacy of an Intravenous Formulation Containing Monomeric Amphotericin B, 5-Fluorocytosine, and Saline for Sodium Supplementation.
    Alvarez C; Andes DR; Kang JY; Krug C; Kwon GS
    Pharm Res; 2017 May; 34(5):1115-1124. PubMed ID: 28205003
    [TBL] [Abstract][Full Text] [Related]  

  • 65. [Sensitivity of Candida to 5-fluorocytosine and amphotericin B].
    Pawlik B; Budak A; Macura A; Laskownicka Z
    Med Dosw Mikrobiol; 1978; 30(1):43-8. PubMed ID: 692181
    [No Abstract]   [Full Text] [Related]  

  • 66. Study of the susceptibility of yeast isolates of clinical interest to five antifungal agents using the E test.
    Linares MJ; Muñoz JF; Solís F; Rodríguez FC; Valero A; Casal M
    Rev Esp Quimioter; 1998 Mar; 11(1):64-9. PubMed ID: 9795292
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Transport of antimicrobial agents using peptide carrier systems: anticandidal activity of m-fluorophenylalanine--peptide conjugates.
    Kingsbury WD; Boehm JC; Mehta RJ; Grappel SF
    J Med Chem; 1983 Dec; 26(12):1725-9. PubMed ID: 6644741
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Practical quantitative assay for 5- fluorocytosine in serum and other body fluids.
    Blaker RG; Doutt BJ
    Antimicrob Agents Chemother; 1972 Dec; 2(6):502-3. PubMed ID: 4596745
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Radiometric method for determining the susceptibility of yeasts to 5-fluorocytosine.
    Hopfer RL; Mills K; Gröschel D
    Antimicrob Agents Chemother; 1979 Feb; 15(2):313-4. PubMed ID: 426519
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Fatty acids as molecular carriers in cleavable antifungal conjugates.
    Nowak M; Skwarecki AS; Pilch J; Górska J; Szweda P; Milewska MJ; Milewski S
    Eur J Med Chem; 2023 Apr; 252():115293. PubMed ID: 36958265
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Asymmetrical dose responses shape the evolutionary trade-off between antifungal resistance and nutrient use.
    Després PC; Cisneros AF; Alexander EMM; Sonigara R; Gagné-Thivierge C; Dubé AK; Landry CR
    Nat Ecol Evol; 2022 Oct; 6(10):1501-1515. PubMed ID: 36050399
    [TBL] [Abstract][Full Text] [Related]  

  • 72. An accelerated stability study of 5-flucytosine in intravenous solution.
    Vermes A; van der Sijs H; Guchelaar HJ
    Pharm World Sci; 1999 Feb; 21(1):35-9. PubMed ID: 10214667
    [TBL] [Abstract][Full Text] [Related]  

  • 73. [Multisite evaluation of a colorimetric broth microdilution antifungal susceptibility testing].
    Yamane N; Igari J
    Rinsho Byori; 1997 Feb; 45(2):190-9. PubMed ID: 9121005
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Anticandidal activity of pyrimidine-peptide conjugates.
    Ti JS; Steinfeld AS; Naider F; Gulumoglu A; Lewis SV; Becker JM
    J Med Chem; 1980 Aug; 23(8):913-8. PubMed ID: 6995613
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Anticandidal activity of 5-fluorocytosine-peptide conjugates.
    Steinfeld AS; Naider F; Becker JM
    J Med Chem; 1979 Sep; 22(9):1104-9. PubMed ID: 385880
    [TBL] [Abstract][Full Text] [Related]  

  • 76. In vitro susceptibility to 5-fluorocytosine and nystatin of common clinical yeast isolates.
    Nobre G; Sobral T; Ferreira AF
    Mycopathologia; 1981 Jan; 73(1):39-41. PubMed ID: 7012631
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Experimental and clinical studies of 5-fluorocytosine activity in Candida ocular infections. I. In vitro activity of 5-fluorocytosine on Candida species isolated from ocular infections.
    Segal E; Romano A; Eylan E; Stein R
    Chemotherapy; 1975; 21(6):358-66. PubMed ID: 1183243
    [TBL] [Abstract][Full Text] [Related]  

  • 78.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 79.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 80.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.